Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Von Eschenbach elaborates on collaboration

This article was originally published in The Gray Sheet

Executive Summary

"We are in a model of healthcare where we are looking at things in fragmented...and segmented opportunities," said FDA Acting Commissioner Andrew von Eschenbach, MD, at a meeting of the Personalized Medicine Coalition in Washington, D.C., March 6. "There will always be separate partitions and individual missions and uniqueness," he said. But we need "to find out how we can partner, integrate and collaborate" to provide the best patient care. Von Eschenbach pointed to a Memorandum of Understanding between FDA, the National Cancer Institute and CMS signed in January as progress on this front. Von Eschenbach could be tapped as the permanent FDA commissioner in the next month and a half...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel